Acta Diabetologica

, Volume 51, Issue 6, pp 941–946 | Cite as

Apolipoprotein B and non-HDL cholesterol are more powerful predictors for incident type 2 diabetes than fasting glucose or glycated hemoglobin in subjects with normal glucose tolerance: a 3.3-year retrospective longitudinal study

  • You-Cheol Hwang
  • Hong-Yup Ahn
  • Sung-Woo Park
  • Cheol-Young Park
Original Article


The association between atherogenic dyslipidemia (AD) and incident type 2 diabetes (T2D) in the low-risk group for T2D has not yet been determined. The aims of this study were to investigate whether AD, characterized by increased serum apoB and non-HDL cholesterol, could predict the development of T2D in subjects with normal glucose tolerance (NGT). A total of 84,394 subjects with NGT (48,906 men and 35,488 women), aged 20–89 years (mean age 38.4 years), were enrolled in this study and were followed for a mean duration of 3.3 years. ApoB and non-HDL cholesterol levels showed stronger associations with the development of T2D compared with conventional lipid measurements and their ratios (HR per 1-SD (95 % CI) 1.27 (1.23–1.30) and 1.27 (1.24–1.29), respectively, both P < 0.001). In multivariate Cox regression models, both apoB and non-HDL cholesterol were associated with the development of T2D, independent of other risk factors for T2D, fasting serum glucose, HbA1c, and conventional lipid measurements such as triglycerides and HDL cholesterol (HR per 1-SD (95 % CI) 1.16 (1.11–1.21) and 1.15 (1.11–1.19), respectively, both P < 0.001). However, fasting serum glucose was not associated with the development of T2D in these models. In conclusion, AD was more closely associated with the development of T2D than fasting glucose or glycated hemoglobin in subjects with NGT.


Apolipoprotein B Non-HDL cholesterol Type 2 diabetes Normal glucose tolerance 


  1. 1.
    Adiels M, Olofsson SO, Taskinen MR, Borén J (2008) Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:1225–1236PubMedCrossRefGoogle Scholar
  2. 2.
    Bamba V, Rader DJ (2007) Obesity and atherogenic dyslipidemia. Gastroenterology 132:2181–2190PubMedCrossRefGoogle Scholar
  3. 3.
    Barter PJ (2011) The causes and consequences of low levels of high-density lipoproteins in patients with diabetes. Diabetes Metab J 35:101–106PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Sniderman AD, Furberg CD, Keech A et al (2003) Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361:777–780PubMedCrossRefGoogle Scholar
  5. 5.
    Kastelein JJ, van der Steeg WA, Holme I et al (2008) Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117:3002–3009PubMedCrossRefGoogle Scholar
  6. 6.
    Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E (2001) High apolipoprotein B, low apolipoprotein A-I and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358:2026–2033PubMedCrossRefGoogle Scholar
  7. 7.
    Thompson A, Danesh J (2006) Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 259:481–492PubMedCrossRefGoogle Scholar
  8. 8.
    Ley SH, Harris SB, Connelly PW et al (2010) Association of apolipoprotein B with incident type 2 diabetes in an aboriginal Canadian population. Clin Chem 56:666–670PubMedCrossRefGoogle Scholar
  9. 9.
    Salomaa V, Havulinna A, Saarela O et al (2010) Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS ONE 5:e10100PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Hwang YC, Ahn HY, Yu SH, Park SW, Park CY (2014) Atherogenic dyslipidaemic profiles associated with the development of Type 2 diabetes: a 3.1-year longitudinal study. Diabet Med 31:24–30PubMedCrossRefGoogle Scholar
  11. 11.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497Google Scholar
  12. 12.
    American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33:S62–S69PubMedCentralCrossRefGoogle Scholar
  13. 13.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRefGoogle Scholar
  14. 14.
    Binnert C, Genoud M, Seematter G et al (2005) Glucose-induced insulin secretion in dyslipidemic and normolipidemic patients with normal glucose tolerance. Diabetes Care 28:1225–1227PubMedCrossRefGoogle Scholar
  15. 15.
    Laakso M, Sarlund H, Mykkänen L (1990) Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis 10:223–231PubMedCrossRefGoogle Scholar
  16. 16.
    Chahil TJ, Ginsberg HN (2006) Diabetic dyslipidemia. Endocrinol Metab Clin North Am 35:491–510PubMedCrossRefGoogle Scholar
  17. 17.
    Samuel VT, Petersen KF, Shulman GI (2010) Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375:2267–2277PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Meigs JB, Nathan DM, Wilson PW, Cupples LA, Singer DE (1998) Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study. Ann Intern Med 128:524–533PubMedCrossRefGoogle Scholar
  19. 19.
    Preiss D, Seshasai SR, Welsh P et al (2011) Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305:2556–2564PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  • You-Cheol Hwang
    • 1
  • Hong-Yup Ahn
    • 2
  • Sung-Woo Park
    • 3
  • Cheol-Young Park
    • 3
  1. 1.Division of Endocrinology and Metabolism, Department of Medicine, Kyung Hee University Hospital at GangdongKyung Hee University School of MedicineSeoulRepublic of Korea
  2. 2.Department of StatisticsDongguk University-SeoulSeoulRepublic of Korea
  3. 3.Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung HospitalSungkyunkwan University School of MedicineSeoulRepublic of Korea

Personalised recommendations